- call +1-201-465-4211
- email sales@mrinsights.biz
ADHD is a brain/neurodevelopmental/neurobehavioral disorder characterized by pervasive and impairing symptoms of inattention, hyperactivity, and impulsivity. The Centers for Disease Control and Prevention (CDC) defines “neurobehavioral” as the way the brain affects emotion, behavior, and learning.
Scope of the Report:
This report studies the Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market by product type and applications/end industries.
Growth in the ADHD therapeutics market is mainly driven by granular impact of changing lifestyles and value systems impacting quality of births, increasing use of additives and preservations in children’s diet, rising prevalence of ADHD among children in the 4–17 year age group, increasing adoption of diagnostic guidelines (statistical manual of mental disorders) with low threshold for diagnosis of ADHD in other regions such as Europe and Latin America. Moreover, increasing awareness regarding ADHD among physicians and patients, and opinion-based diagnosis of ADHD owing to lack of standard diagnostic tests is expected to boost revenue growth of the global ADHD therapeutics market in the near future. However, existence of comorbid conditions in children leads to underdiagnoses of ADHD and less availability of non-stimulants ADHD drugs in various geographies. These are factors expected to restrain growth of the market over the forecast period.
The global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
Eli Lilly and Company
Novartis
Shire
Pfizer
GlaxoSmithKline
Mallinckrodt Pharmaceuticals
Hisamitsu Pharmaceutical
Impax Laboratories
Johnson ＆Johnson
UCB
Purdue Parma
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Stimulants
Non-Stimulants
Market Segment by Applications, can be divided into
Specialty Clinics
Hospital Pharmacies
Retail Pharmacies
E-Commerce
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Overview
1.1 Product Overview and Scope of Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics
1.2 Classification of Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics by Types
1.2.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Types in 2017
1.2.3 Stimulants
1.2.4 Non-Stimulants
1.3 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market by Application
1.3.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Specialty Clinics
1.3.3 Hospital Pharmacies
1.3.4 Retail Pharmacies
1.3.5 E-Commerce
1.4 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market by Regions
1.4.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 Eli Lilly and Company
2.1.1 Business Overview
2.1.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Eli Lilly and Company Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis
2.2.1 Business Overview
2.2.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 Shire
2.3.1 Business Overview
2.3.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Shire Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Pfizer
2.4.1 Business Overview
2.4.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Pfizer Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 GlaxoSmithKline
2.5.1 Business Overview
2.5.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 GlaxoSmithKline Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Mallinckrodt Pharmaceuticals
2.6.1 Business Overview
2.6.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Mallinckrodt Pharmaceuticals Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Hisamitsu Pharmaceutical
2.7.1 Business Overview
2.7.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Hisamitsu Pharmaceutical Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Impax Laboratories
2.8.1 Business Overview
2.8.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Impax Laboratories Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.9 Johnson ＆Johnson
2.9.1 Business Overview
2.9.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Johnson ＆Johnson Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.10 UCB
2.10.1 Business Overview
2.10.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Type and Applications
2.10.2.1 Product A
2.10.2.2 Product B
2.10.3 UCB Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.11 Purdue Parma
2.11.1 Business Overview
2.11.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Type and Applications
2.11.2.1 Product A
2.11.2.2 Product B
2.11.3 Purdue Parma Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Competition, by Players
3.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players Market Share
3.2.2 Top 10 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size by Regions
4.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Market Share by Regions
4.2 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries
5.1 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries (2013-2018)
5.2 USA Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries
6.1 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries
7.1 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries (2013-2018)
7.2 China Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries
8.1 South America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics by Countries
9.1 Middle East and Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Segment by Type
10.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Forecast by Type (2018-2023)
10.3 Stimulants Revenue Growth Rate (2013-2023)
10.4 Non-Stimulants Revenue Growth Rate (2013-2023)
11 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Segment by Application
11.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Forecast by Application (2018-2023)
11.3 Specialty Clinics Revenue Growth (2013-2018)
11.4 Hospital Pharmacies Revenue Growth (2013-2018)
11.5 Retail Pharmacies Revenue Growth (2013-2018)
11.6 E-Commerce Revenue Growth (2013-2018)
12 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Forecast (2018-2023)
12.1 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Size Forecast (2018-2023)
12.2 Global Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics Picture
Table Product Specifications of Attention-Deficit Hyperactivity Disorder (ADHD) Therapeutics
Tab
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
